Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology
Abstract Monoclonal antibodies (Mabs) have become key drugs in cancer treatment, either as targeted therapies or more recently as immune checkpoint inhibitors (ICIs). The fact that only some patients benefit from these drugs poses the usual question in the field of onco‐hematology: that of the benef...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-04-01
|
Series: | Pharmacology Research & Perspectives |
Online Access: | https://doi.org/10.1002/prp2.757 |
id |
doaj-de932d7a0fe14f119b38e5a85bccf4de |
---|---|
record_format |
Article |
spelling |
doaj-de932d7a0fe14f119b38e5a85bccf4de2021-10-01T09:16:20ZengWileyPharmacology Research & Perspectives2052-17072021-04-0192n/an/a10.1002/prp2.757Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncologyEtienne Chatelut0Jeroen J. M. A. Hendrikx1Jennifer Martin2Joseph Ciccolini3Dirk Jan A. R. Moes4CRCTUniversité de ToulouseInserm, and Institut Claudius‐RegaudIUCT‐Oncopole Toulouse FranceDepartment of Pharmacy and Pharmacology and Department of Nuclear Medicine The Netherlands Cancer Institute Amsterdam The NetherlandsCentre for Drug Repurposing and Medicines Research The University of Newcastle Callaghan NSW AustraliaSMARTcCRCM Inserm U1068Aix Marseille University and La Timone university Hospital of Marseille Marseille FranceDepartment of Clinical Pharmacy and Toxicology Leiden University Medical Center Leiden The NetherlandsAbstract Monoclonal antibodies (Mabs) have become key drugs in cancer treatment, either as targeted therapies or more recently as immune checkpoint inhibitors (ICIs). The fact that only some patients benefit from these drugs poses the usual question in the field of onco‐hematology: that of the benefit of individual dosing and the potential of therapeutic drug monitoring (TDM) to carry out this individualization. However, Mabs present unique pharmacological characteristics for TDM, and the pharmacokinetic–pharmacodynamic relationship observed should be interpreted differently than that observed for conventional drugs and small molecules. This pharmacology practice review has been summarized from a public debate between the authors at the International TDM and Clinical Toxicology meeting in Banff, 2020, regarding the potential roles of TDM in the Mab/ICI setting.https://doi.org/10.1002/prp2.757 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Etienne Chatelut Jeroen J. M. A. Hendrikx Jennifer Martin Joseph Ciccolini Dirk Jan A. R. Moes |
spellingShingle |
Etienne Chatelut Jeroen J. M. A. Hendrikx Jennifer Martin Joseph Ciccolini Dirk Jan A. R. Moes Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology Pharmacology Research & Perspectives |
author_facet |
Etienne Chatelut Jeroen J. M. A. Hendrikx Jennifer Martin Joseph Ciccolini Dirk Jan A. R. Moes |
author_sort |
Etienne Chatelut |
title |
Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology |
title_short |
Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology |
title_full |
Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology |
title_fullStr |
Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology |
title_full_unstemmed |
Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology |
title_sort |
unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology |
publisher |
Wiley |
series |
Pharmacology Research & Perspectives |
issn |
2052-1707 |
publishDate |
2021-04-01 |
description |
Abstract Monoclonal antibodies (Mabs) have become key drugs in cancer treatment, either as targeted therapies or more recently as immune checkpoint inhibitors (ICIs). The fact that only some patients benefit from these drugs poses the usual question in the field of onco‐hematology: that of the benefit of individual dosing and the potential of therapeutic drug monitoring (TDM) to carry out this individualization. However, Mabs present unique pharmacological characteristics for TDM, and the pharmacokinetic–pharmacodynamic relationship observed should be interpreted differently than that observed for conventional drugs and small molecules. This pharmacology practice review has been summarized from a public debate between the authors at the International TDM and Clinical Toxicology meeting in Banff, 2020, regarding the potential roles of TDM in the Mab/ICI setting. |
url |
https://doi.org/10.1002/prp2.757 |
work_keys_str_mv |
AT etiennechatelut unravelingthecomplexityoftherapeuticdrugmonitoringformonoclonalantibodytherapiestoindividualizedoseinoncology AT jeroenjmahendrikx unravelingthecomplexityoftherapeuticdrugmonitoringformonoclonalantibodytherapiestoindividualizedoseinoncology AT jennifermartin unravelingthecomplexityoftherapeuticdrugmonitoringformonoclonalantibodytherapiestoindividualizedoseinoncology AT josephciccolini unravelingthecomplexityoftherapeuticdrugmonitoringformonoclonalantibodytherapiestoindividualizedoseinoncology AT dirkjanarmoes unravelingthecomplexityoftherapeuticdrugmonitoringformonoclonalantibodytherapiestoindividualizedoseinoncology |
_version_ |
1716861894752468992 |